Accueil
Détail de l'auteur
Auteur H. HAGAN |
Documents disponibles écrits par cet auteur (43)
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Livre
Z. SLOBODA ; E. M. ADLAF ; M. D. ANGLIN ; M. L. BRECHT ; J. D. COLLIVER ; K. P. CONWAY ; D. C. DES JARLAIS ; K. W. ELIFSON ; S. R. FRIEDMAN ; C. FRY ; M. D. GLANTZ ; P. GRIFFITHS ; H. HAGAN ; W. HALL ; M. HICKMAN ; Y. I. HSER ; R. L. HUBBARD ; N. J. KOZEL ; T. LOCKE ; D. LONGSHORE ; R. McKETIN ; M. D. NEWCOMB ; J. A. RESKO ; C. E. STERK ; C. TAYLOR ; C. WALKER ; T. A. WILLS | New York : Springer Inc. | 2005ENGLISH : As the drug abuse epidemic evolves, so do the tools needed to understand and treat it. Accordingly, Epidemiology of Drug Abuse takes the long view, cogently outlining what the book calls "the natural history of drug abuse" and redefi[...]Article : Périodique
R. D. BURT ; H. HAGAN ; K. SABIN ; H. THIEDE |PURPOSE: To empirically evaluate respondent-driven sampling (RDS) recruitment methods, which have been proposed as an advantageous means of surveying hidden populations. METHODS: The National HIV Behavioral Surveillance system used RDS to recrui[...]Article : Périodique
D. C. DES JARLAIS ; K. ARASTEH ; J. FEELEMYER ; C. McKNIGHT ; D. M. BARNES ; S. TROSS ; D. C. PERLMAN ; A. N. C. CAMPBELL ; H. L. F. COOPER ; H. HAGAN |Objectives: Transitioning from injecting to non-injecting routes of drug administration can provide important individual and community health benefits. We assessed characteristics of persons who had ceased injecting while continuing to use heroi[...]Périodique
S. M. STRAUSS ; J. ASTONE ; VASSILEV Z. P. ; D. C. DES JARLAIS ; H. HAGAN | 2003ENGLISH : Drug treatment programs are sites of opportunity for the delivery of hepatitis C (HCV) prevention and care services to drug users. Using data collected from a random nationwide sample (N = 595) of drug treatment programs in the Unite[...]Article : Périodique
P. K. NELSON ; B. M. MATHERS ; B. COWIE ; H. HAGAN ; D. C. DES JARLAIS ; D. HORYNIAK ; L. DEGENHARDT |BACKGROUND: Injecting drug use is an important risk factor for transmission of viral hepatitis, but detailed, transparent estimates of the scale of the issue do not exist. We estimated national, regional, and global prevalence and population siz[...]Article : Périodique
D. J. SMITH ; J. COMBELLICK ; A. E. JORDAN ; H. HAGAN |Background: Understanding HCV disease progression rates among people who inject drugs (PWID) is important to setting policy to expand access to detection, diagnosis and treatment, and in forecasting the burden of disease. In this paper we synthe[...]Périodique
H. HAGAN | 1998FRANÇAIS : Après une description des caractéristiques du virus de l'hépatite C (VHC), cet article examine les études publiées sur la séroépidémiologie du VHC chez les toxicomanes par injection en relation avec l'épidémiologie du VIH et de l'hép[...]Article : Périodique
DEIBERT R.J. ; GOLDBAUM G. ; T. R. PARKER ; H. HAGAN ; R. MARKS ; HANRAHAN M. ; H. THIEDE |ENGLISH : We examined pharmacists' attitudes and practices related to syringe sales to injection drug users before and after legal reform and local programming to enhance sterile syringe access. We replicated a 1996 study by conducting pharmac[...]Article : Périodique
Aims - We conducted a systematic review of studies reporting seroincidence of hepatitis C infection (HCV) in relation to shared syringes and drug preparation equipment among injection drug users (IDUs). We identified published and unpublished st[...]Article : Périodique
The authors examined the relation between time since onset of illicit drug injection (time at risk) and rates of hepatitis C virus (HCV) infection by using meta-regression. In 72 prevalence studies, median time since onset of injection was 7.24 [...]Article : Périodique
L. PLATT ; S. MINOZZI ; J. REED ; P. VICKERMAN ; H. HAGAN ; C. FRENCH ; A. JORDAN ; L. DEGENHARDT ; V. HOPE ; S. HUTCHINSON ; L. MAHER ; N. PALMATEER ; A. TAYLOR ; J. BRUNEAU ; M. HICKMAN |Aims: To estimate the effects of needle and syringe programmes (NSP) and opioid substitution therapy (OST), alone or in combination, for preventing acquisition of hepatitis C virus (HCV) in people who inject drugs (PWID). Methods: Systematic re[...]Article : Périodique
L. PLATT ; S. MINOZZI ; J. REED ; P. VICKERMAN ; H. HAGAN ; C. FRENCH ; A. JORDAN ; L. DEGENHARDT ; V. HOPE ; S. HUTCHINSON ; L. MAHER ; N. PALMATEER ; A. TAYLOR ; J. BRUNEAU ; M. HICKMAN |Review question: We examine research on the effect of needle syringe programmes (NSP) and opioid substitution treatment (OST) in reducing the risk of becoming infected with the hepatitis C virus. Background: There are around 114.9 million peopl[...]Article : Périodique
M. E. MACKESY-AMITI ; L. FINNEGAN ; L. J. OUELLET ; E. T. GOLUB ; H. HAGAN ; S. M. HUDSON ; M. H. LATKA ; R. S. GARFEIN |We analyzed data from a large randomized HIV/HCV prevention intervention trial with young injection drug users (IDUs) conducted in five U.S. cities. The trial compared a peer education intervention (PEI) with a time-matched, attention control gr[...]Périodique
R. S. GARFEIN ; E. T. GOLUB ; A. E. GREENBERG ; H. HAGAN ; D. L. HANSON ; S. M. HUDSON ; F. KAPADIA ; M. H. LATKA ; L. J. OUELLET ; D. W. PURCELL ; S. A. STRATHDEE ; H. THIEDE | 2007OBJECTIVES: To evaluate whether a behavioral intervention, which taught peer education skills, could reduce injection and sexual risk behaviors associated with primary HIV and hepatitis C virus infection (HCV) among young injection drug users (I[...]Article : Périodique
AIMS This study conducted a secondary analysis to examine injection cessation and decreasing frequency of injection during a multi-site randomized controlled HIV prevention intervention trial that sought to reduce sexual and injection risk behav[...]